Nikko Asset Management Americas, Inc. Sarepta Therapeutics, Inc. Transaction History

Nikko Asset Management Americas, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 09, 2021	SELL	$69.38 - $86.75 $13.4 Million - $16.7 Million	-192,650 Closed	0 $0
Q1 2021 May 03, 2021	BUY	$72.25 - $168.95 $7.89 Million - $18.5 Million	109,226 Added 130.93%	192,650 $14.4 Million
Q4 2020 Feb 11, 2021	BUY	$125.56 - $178.74 $3.38 Million - $4.81 Million	26,886 Added 47.55%	83,424 $14.2 Million
Q3 2020 Nov 02, 2020	SELL	$127.12 - $172.34 $694,456 - $941,493	-5,463 Reduced 8.81%	56,538 $7.63 Million
Q2 2020 Aug 07, 2020	SELL	$93.0 - $171.7 $4.4 Million - $8.13 Million	-47,334 Reduced 43.29%	62,001 $9.63 Million
Q1 2020 Apr 30, 2020	SELL	$82.38 - $131.64 $1.03 Million - $1.65 Million	-12,520 Reduced 10.27%	109,335 $10.7 Million
Q4 2019 Feb 06, 2020	SELL	$76.53 - $135.58 $211,835 - $375,285	-2,768 Reduced 2.22%	121,855 $15.7 Million
Q3 2019 Oct 29, 2019	BUY	$72.81 - $156.91 $2.7 Million - $5.83 Million	37,131 Added 42.44%	124,623 $9.39 Million
Q2 2019 Jul 29, 2019	BUY	$112.21 - $151.95 $4.94 Million - $6.7 Million	44,061 Added 101.45%	87,492 $13.3 Million
Q1 2019 Apr 30, 2019	BUY	$106.67 - $151.68 $4.63 Million - $6.59 Million	43,431 New	43,431 $5.18 Million

529

84.2M

2.06M

1.52M

Ticker SRPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,567,904
Market Cap $10.4B
Description
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...

Get notified when there are updates to the investment portfolio of Nikko Asset Management Americas, Inc., based on Form 13F filings with the SEC.

Stay updated on Nikko Asset Management Americas, Inc. with notifications on news.